A Seamless Phase IIa/IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy for Symptomatic Treatment in Subjects With Alzheimer's Disease

Trial Profile

A Seamless Phase IIa/IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy for Symptomatic Treatment in Subjects With Alzheimer's Disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs MK 7622 (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 18 Apr 2016 Status changed from active, no longer recruiting to discontinued.
    • 24 Mar 2016 Planned End Date changed from 1 Apr 2020 to 1 Apr 2016 as per ClinicalTrials.gov record.
    • 24 Mar 2016 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top